ARTH Arch Therapeutics Inc

USD 0.96 0.00 0
Icon

Arch Therapeutics Inc (ARTH) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | OTC
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.96

0.00 (0.00)%

USD 4.67M

N/A

N/A

N/A

Icon

ARTH

Arch Therapeutics Inc (USD)
COMMON STOCK | OTC
USD 0.96
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 4.67M

N/A

USD 0.96

Arch Therapeutics Inc (ARTH) Stock Forecast

N/A

Based on the Arch Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Arch Therapeutics Inc is not available over the next 12 months. Arch Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Arch Therapeutics Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Arch Therapeutics Inc’s stock price was USD 0.96. Arch Therapeutics Inc’s stock price has changed by -4.00% over the past week, -11.93% over the past month and -67.57% over the last year.

No recent analyst target price found for Arch Therapeutics Inc
No recent average analyst rating found for Arch Therapeutics Inc

Company Overview Arch Therapeutics Inc

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery,...Read More

235 Walnut Street, Framingham, MA, United States, 01702

8

September

USD

USA

Adjusted Closing Price for Arch Therapeutics Inc (ARTH)

Loading...

Unadjusted Closing Price for Arch Therapeutics Inc (ARTH)

Loading...

Share Trading Volume for Arch Therapeutics Inc Shares

Loading...

Compare Performance of Arch Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ARTH

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Arch Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF
Novo Nordisk A/S +1.35 (+1.01%) USD632.23B 48.44 4.92

ETFs Containing ARTH

Symbol Name ARTH's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Arch Therapeutics Inc (ARTH) Stock

Stock Target Advisor's fundamental analysis for Arch Therapeutics Inc's stock is Bearish.

Unfortunately we do not have enough data on ARTH's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on ARTH's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on ARTH's stock to indicate if its overvalued.

The last closing price of ARTH's stock was USD 0.96.

The most recent market capitalization for ARTH is USD 4.67M.

Unfortunately we do not have enough analyst data on ARTH's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Arch Therapeutics Inc's stock.

As per our most recent records Arch Therapeutics Inc has 8 Employees.

Arch Therapeutics Inc's registered address is 235 Walnut Street, Framingham, MA, United States, 01702. You can get more information about it from Arch Therapeutics Inc's website at https://www.archtherapeutics.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...